← Back to Search

Behavioural Intervention

Virtual Reality for OCD (VR-TMS Trial)

N/A
Waitlist Available
Led By Sina Nikayin, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be at least 18 years old
Be older than 18 years old
Must not have
Unable to provide informed consent
History of seizure disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 1 hour after each treatment session
Awards & highlights
No Placebo-Only Group

Summary

This trial will look at how Virtual Reality technology can help patients with Obsessive-Compulsive Disorder who are undergoing treatment with Transcranial Magnetic Stimulation.

Who is the study for?
This trial is for adults with OCD who are deemed suitable for TMS treatment by a Yale psychiatrist. Participants must be willing to follow the study's procedures and requirements, understand English, and not have hearing or visual impairments that would affect VR use.
What is being tested?
The study examines how using Virtual Reality (VR) technology before Transcranial Magnetic Stimulation (TMS) can impact the treatment of Obsessive-Compulsive Disorder (OCD).
What are the potential side effects?
Potential side effects may include discomfort from wearing VR equipment, temporary disorientation or nausea related to VR experiences, and typical TMS-related side effects like scalp discomfort or headache.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to understand and agree to the study's details on my own.
Select...
I have a history of seizures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 1 hour after each treatment session
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 1 hour after each treatment session for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Tolerability of VR treatment by qualitative assessment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment GroupExperimental Treatment1 Intervention
This single arm will include all participants of the study, who will all receive the intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Virtual Reality
2017
Completed Phase 3
~1580

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,453 Total Patients Enrolled
13 Trials studying Obsessive-Compulsive Disorder
842 Patients Enrolled for Obsessive-Compulsive Disorder
Sina Nikayin, MDPrincipal InvestigatorAssistant Professor, Departement of Psychiatry, Yale University
2 Previous Clinical Trials
44 Total Patients Enrolled
~3 spots leftby Dec 2025